红景天注射液治疗非ST抬高心肌梗死的疗效分析

An effective analysis of treating non-ST elevation myocardial infarction with the Hongjingtian injection

目的:探究红景天注射液治疗非ST抬高心肌梗死(NSTEMI)的有效性与安全性。方法:入选80例NSTEMI患者随机分为治疗组(40例)和对照组(40例),对照组给予低分子肝素、氯吡格雷、阿司匹林和其他基础治疗,治疗组在此基础上给予红景天注射液,比较两组的基础临床情况、疗效、30d内主要心脏不良事件发生率,包括死亡、新近发生急性心肌梗死、靶血管血运重建、出血并发症及其他不良反应。结果:两组基础临床情况相同。治疗组临床疗效、心绞痛缓解、缺血性心电图改善均优于对照组(P<0.05)。治疗组左心衰竭发生率、30d内MACEs发生率均低于对照组(2.5%VS 15.0%,7.5%VS 22.5%,P<0.05)。两组均无肝肾功能损害等其他不良反应。结论:红景天注射液能改善NSTEMI患者的临床症状、心肌灌注、心功能,减少30d内主要心脏不良事件发生,疗效确切,安全性好。

Objective:To investigate the efficacy and safety of the Hongjingtian injection on non-ST elevation acute myocardial infarction.Methods:80patients were randomly and divided into the Hongjingtian injection group and the control group,40cases for each.The control group received low molecular weight heparin,clopidogrel,aspirin and other basic treatment.The treatment group took the Hongjingtian injection more.Results:Basic situation in two groups were same.Clinical efficacy,angina,ischemic electrocardiogram improvement in the treatment group were better than those in the control group(P<0.05).The incidence of left ventricular failure in the treatment group was lower than that in the control group(2.5%VS15.0%,7.5%VS22.5%,P<0.05).Both groups had no adverse effect such as liver and kidney damage.Conclusion:The Hongjingtian injection can improve clinical symptoms,myocardial perfusion and cardiac function of NSTEMI patients,and reduce the occurrence of major cardiac adverse events within30days.The curative effect is correct and the safety is good.